Optical Bedside Monitoring of Cerebral Blood Flow in Acute Ischemic Stroke Patients During Head-of-Bed Manipulation

Christopher G. Favilla, MD*; Rickson C. Mesquita, PhD*; Michael Mullen, MD; Turgut Durduran, PhD; Xiangping Lu, MD; Meeri K. Kim, PhD; David L. Minkoff, BA; Scott E. Kasner, MD; Joel H. Greenberg, PhD; Arjun G. Yodh, PhD; John A. Detre, MD

Background and Purpose—A primary goal of acute ischemic stroke (AIS) management is to maximize perfusion in the affected region and surrounding ischemic penumbra. However, interventions to maximize perfusion, such as flat head-of-bed (HOB) positioning, are currently prescribed empirically. Bedside monitoring of cerebral blood flow (CBF) allows the effects of interventions such as flat HOB to be monitored and may ultimately be used to guide clinical management.

Methods—Cerebral perfusion was measured during HOB manipulations in 17 patients with unilateral AIS affecting large cortical territories in the anterior circulation. Simultaneous measurements of frontal CBF and arterial flow velocity were performed with diffuse correlation spectroscopy and transcranial Doppler ultrasound, respectively. Results were analyzed in the context of available clinical data and a previous study.

Results—Frontal CBF, averaged over the patient cohort, decreased by 17% (P=0.034) and 15% (P=0.011) in the ipsilesional and contralesional hemispheres, respectively, when HOB was changed from flat to 30°. Significant (cohort-averaged) changes in blood velocity were not observed. Individually, varying responses to HOB manipulation were observed, including paradoxical increases in CBF with increasing HOB angle. Clinical features, stroke volume, and distance to the optical probe could not explain this paradoxical response.

Conclusions—A lower HOB angle results in an increase in cortical CBF without a significant change in arterial flow velocity in AIS, but there is variability across patients in this response. Bedside CBF monitoring with diffuse correlation spectroscopy provides a potential means to individualize interventions designed to optimize CBF in AIS. (Stroke. 2014;45:1269-1274.)

Key Words: perfusion ■ spectroscopy, near-infrared ■ stroke

Optimization of cerebral blood flow (CBF) in an effort to salvage as much of the ischemic penumbra as possible is a major goal in the management of acute ischemic stroke (AIS). Cerebrovascular autoregulation is thought to be impaired after AIS.1,2 Accordingly, interventions such as withholding antihypertensive medications, intravenous hydration, and the use of a flat head of bed (HOB) are typically used to maximize CBF.3-5 However, CBF is rarely measured in AIS, and the effects of such interventions on CBF remain largely unknown.

Quantification of CBF is challenging. The current gold standard is 15O-PET,6 but this modality is complicated, expensive, and exposes patients to ionizing radiation. Other techniques such as MRI7,8 and CT perfusion are available but only provide isolated measures rather than continuous monitoring. Furthermore, all of these modalities are restricted to supine patients and are hence unable to measure the responses to HOB manipulations. Serial measurements are challenging with these methods because of radiation exposure, cost, and logistical considerations.

Transcranial Doppler (TCD) monitoring, which quantifies blood flow velocity in large vessels such as the middle cerebral artery (MCA), has been used as a surrogate measure of CBF. The coefficient of proportionality between flow and velocity is the vessel cross-sectional area, but a constant arterial diameter may not apply in AIS.9,10 More importantly, TCD measures velocity through the MCA trunk, but local microvascular flow to brain parenchyma also includes potential collateral sources, particularly in the setting of AIS. Despite these limitations, TCD-based mean flow velocity (MFV) has been used for bedside CBF assessment, and MFV has been observed to increase with lowering HOB angle.3,11

© 2014 American Heart Association, Inc.

Received November 13, 2013; final revision received January 24, 2014; accepted February 18, 2014.


Guest Editor for this article was Markku Kaste, MD, PhD.

*Drs Favilla and Mesquita are joint first authors and contributed equally.

The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.113.004116/-/DC1.

Correspondence to John A. Detre, MD, Department of Neurology, University of Pennsylvania, 3400 Spruce St, 3 West Gates, Philadelphia, PA 19104-4283. E-mail detre@mail.med.upenn.edu

© 2014 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.113.004116

1269
Recently, diffuse correlation spectroscopy (DCS) has been demonstrated as a noninvasive transcranial optical method for measuring microvascular cortical CBF.\textsuperscript{12–14} Although DCS provides limited depth penetration into brain parenchyma and, to date, has been limited to measurements over the frontal lobe, the methodology is noninvasive and holds promise as a real-time bedside CBF monitor.\textsuperscript{15,16} Importantly, DCS has been validated against other measures of CBF, such as arterial spin labeling MRI,\textsuperscript{17} Xenon CT,\textsuperscript{18} TCD,\textsuperscript{19} phase-encoded velocity mapping MRI,\textsuperscript{20} and fluorescent microscopes.\textsuperscript{21}

Preliminary work has shown that DCS is sensitive to changes in frontal CBF with HOB angle manipulation in AIS patients.\textsuperscript{22} The current study aims to replicate these preliminary results and to correlate CBF changes with TCD and clinical data.

**Methods**

**Patients**

Eighteen patients with unilateral AIS affecting large cortical territories in the anterior circulation were enrolled at the Hospital of the University of Pennsylvania. One patient lacked temporal windows for TCD and was excluded. The study protocol was initiated <72 hours after symptom onset. National Institutes of Health Stroke Scale, demographics, vascular risk factors, modified Rankin Scale, and stroke diagnostics were performed, including evaluation of outliers and of model residuals.

**HOB Manipulation Protocol**

HOB angles of 0°, 15°, 30°, 0°, −5°, and 0° were sequentially evaluated for 5 minutes each. Measurements at 0° (supine) were recorded as the baseline, against which all subsequent angles were compared. HOB angle was manipulated using the adjustable hospital bed, so that the lower body remained flat whereas the angle of interest was applied to the upper body. Continuous noninvasive blood pressure was recorded with a Finapres (Finapres Medical Systems, Arnhem, the Netherlands).

**Blood Flow Measurements**

DCS provides a transcranial measurement of relative CBF. Briefly, temporal fluctuations of near-infrared light scattered by moving red blood cells in tissue are detected. These fluctuations are quantified by the intensity temporal autocorrelation function. Its decay rate is termed as a noninvasive transcranial optical method for measuring microvascular cortical CBF.\textsuperscript{12–14} Although DCS provides limited depth penetration into brain parenchyma and, to date, has been limited to measurements over the frontal lobe, the methodology is noninvasive and holds promise as a real-time bedside CBF monitor.\textsuperscript{15,16} Importantly, DCS has been validated against other measures of CBF, such as arterial spin labeling MRI,\textsuperscript{17} Xenon CT,\textsuperscript{18} TCD,\textsuperscript{19} phase-encoded velocity mapping MRI,\textsuperscript{20} and fluorescent microscopes.\textsuperscript{21}

Preliminary work has shown that DCS is sensitive to changes in frontal CBF with HOB angle manipulation in AIS patients.\textsuperscript{22} The current study aims to replicate these preliminary results and to correlate CBF changes with TCD and clinical data.

**Blood Flow Measurements**

DCS provides a transcranial measurement of relative CBF. Briefly, temporal fluctuations of near-infrared light scattered by moving red blood cells in tissue are detected. These fluctuations are quantified by the intensity temporal autocorrelation function. Its decay rate is related to changes in CBF.\textsuperscript{22} The instrument used two 785-nm lasers and 8 detectors.

The optical probes were coupled to the head via 2×5 cm foam pads placed bilaterally at the temporal margin of the forehead superior to the frontal sinuses to measure the anterior MCA distribution. The distance between the source and detector fibers was 2.5 cm, permitting light penetration to the cortical surface (≈1.25 cm). Data were collected from both hemispheres every 3 seconds. At each HOB angle, the median blood flow was calculated after discarding the first 30 seconds after a HOB change to avoid potentially spurious motion-induced signal fluctuations.

**Blood Velocity Measurements**

MFV was assessed on all patients using a Spencer Technologies ST3 TCD System. Probes were secured using a Marc 600 Headframe. MCA trunks were insonated bilaterally via transtemporal windows at a depth of 40 to 65 mm. For each HOB angle, MFV was calculated for both MCA trunks after discarding the first 30 seconds after a HOB change to avoid motion-induced signal fluctuations.

**Statistical Analysis**

Median flow and velocity values for each HOB angle were compared with baseline values (0°) in a paired fashion using the Wilcoxon signed-rank test. Spearman correlation was used to compare velocity and CBF changes across HOB angles. Mixed-effects linear regression was used to assess the relationship between HOB angle and both CBF and MFV using restricted maximum likelihood. Models incorporated a random slope, and the covariance was modeled as unstructured. Model results were compared across a range of assumptions and found to be insensitive to model specification. Regression diagnostics were performed, including evaluation of outliers and of model residuals.

In a post hoc analysis, data from this study were pooled with data from 17 patients from a previous study with a similar HOB protocol, but without TCD data.\textsuperscript{22} This previous study had the same inclusion/exclusion criteria, and CBF was measured by DCS across the same HOB angles. The pooled patients (n=34) were dichotomously characterized as having an expected response to HOB manipulation, in which CBF increased with lower HOB position, or a paradoxical response, in which CBF decreased or did not change with lower HOB. Patient characteristics were compared between the 2 groups using Fisher exact test or Wilcoxon rank-sum as appropriate. The influence of large artery occlusion (identified by CTA) on CBF was examined using the Wilcoxon signed-rank test. Analyses were performed with Stata/SE version 10.0 (StataCorp, College Station, TX).

**Results**

HOB manipulation did not result in any transient worsening or improvement in neurological deficits. No side effects were reported, and probes were well tolerated in all patients. Cohort characteristics are described in Table 1. Figure 1 provides an example of raw CBF and MFV data from 1 patient.

**Table 1.** Demographics and Baseline Clinical Features

<table>
<thead>
<tr>
<th></th>
<th>Cohort (n=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>66 (9.8)</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>59</td>
</tr>
<tr>
<td>White race, %</td>
<td>47</td>
</tr>
<tr>
<td>Left hemisphere, %</td>
<td>47</td>
</tr>
<tr>
<td>Days after stroke</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>NIHSS at presentation</td>
<td>12 (6.7)</td>
</tr>
<tr>
<td>NIHSS at time of study</td>
<td>10 (6.0)</td>
</tr>
<tr>
<td>NIHSS at time of discharge</td>
<td>9 (5.0)</td>
</tr>
<tr>
<td>Modified Rankin Scale</td>
<td>3 (1.2)</td>
</tr>
<tr>
<td>Stroke volume, cm³</td>
<td>22 (25.5)</td>
</tr>
<tr>
<td>ASPECT score</td>
<td>7 (2.0)</td>
</tr>
<tr>
<td>Distance (probe to infarct edge), cm</td>
<td>3.8 (1.6)</td>
</tr>
<tr>
<td>Ejection fraction</td>
<td>52 (16.6)</td>
</tr>
<tr>
<td>Medical comorbidities</td>
<td></td>
</tr>
<tr>
<td>HTN</td>
<td>88%</td>
</tr>
<tr>
<td>CHF</td>
<td>35%</td>
</tr>
<tr>
<td>AF</td>
<td>41%</td>
</tr>
<tr>
<td>Previous stroke/TIA</td>
<td>35%</td>
</tr>
<tr>
<td>HLD</td>
<td>82%</td>
</tr>
<tr>
<td>Medications at time of study</td>
<td></td>
</tr>
<tr>
<td>β-Blocker</td>
<td>41%</td>
</tr>
<tr>
<td>Nodal calcium channel blocker</td>
<td>0%</td>
</tr>
<tr>
<td>Digoxin</td>
<td>12%</td>
</tr>
</tbody>
</table>

All values are reported as mean (SD) or percentage for dichotomous variables. AF indicates atrial fibrillation; ASPECT, Alberta Stroke Program Early CT; CHF, congestive heart failure; HLD, hyperlipidemia; HTN, hypertension; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischaemic attack.
Figure 1. Cerebral blood flow (by diffuse correlation spectroscopy) and mean flow velocity (by transcranial Doppler) at each head-of-bed angle for an individual patient.

Variability was also seen in TCD-measured velocity changes, albeit to a lesser extent. However, although DCS identified changes in CBF among paradoxical responders, TCD failed to identify changes in MFV. In the contralesional hemisphere of patients with expected response to HOB manipulation, CBF also decreased when raising HOB to 30° (25%±28%; \( P=0.002 \)), but to a lesser extent than the ipsilesional hemisphere (Figure 3A). In paradoxical responders, contralesional CBF did not change significantly at 30° as compared with a flat HOB (\( P=0.51 \)).

In a post hoc analysis, the 17 patients in this cohort were pooled with 17 patients from a previous study of HOB manipulation in AIS. When compared with this cohort, the 17 patients from the previous study were similar with respect to age (\( P=0.82 \)), National Institutes of Health Stroke Scale (\( P=0.33 \)), stroke volume (\( P=0.13 \)), Alberta Stroke Program Early CT score (\( P=0.62 \)), and distance between stroke and DCS probe (\( P=0.24 \)). Medical comorbidities were present in similar proportions. Five patients (29%) in each cohort showed a paradoxical response. These 10 subjects in the pooled analysis were compared with patients that demonstrated an expected response to HOB manipulation; however, no differences were found with respect to the clinical or radiological features (Table 3). Individual patient responses to HOB positioning for the combined cohort are depicted in Figure 1B in the online-only Data Supplement.

An additional post hoc analysis of these pooled data dichotomized patients based on the presence or absence of ipsilesional large vessel occlusion. Patients with vessel occlusion (n=12) had a 40(±38)% increase in ipsilesional CBF at 0° as compared with 30° (\( P=0.004 \)) and a 21(±34)% contralesional increase in CBF (\( P=0.13 \)). Patients without vessel occlusion (n=22) had a 16(±36)% increase in ipsilesional CBF (\( P=0.08 \)) and a 21(±34)% increase in contralesional CBF (\( P=0.003 \)). Among those with TCD data available, no change in ipsilesional blood velocity was observed in patients with (n=8); 100% versus 95%; \( P=0.47 \)) and without vessel occlusion (n=9; 100% versus 101%; \( P=0.75 \)).

Discussion

DCS provides the means to assess microvascular cortical CBF at bedside in a safe, well-tolerated manner. Previous studies of DCS have quantitatively examined the penetration of DCS signals into the brain. At a source–detector separation of 2.5 cm, as used in this study, the optical signal is predominately a

Figure 2. Average cerebral hemodynamic measurements for all patients across a range of head-of-bed angles. Cerebral blood flow (A) and mean flow velocity (B). Error bars represent standard deviation. DCS indicates diffuse correlation spectroscopy; and TCD, transcranial Doppler. *\( P<0.05 \) by Wilcoxon signed-rank test.
Table 2. Mixed-Effects Linear Regression: Head-of-Bed Angle

<table>
<thead>
<tr>
<th></th>
<th>Coefficient</th>
<th>Wald Z score</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebral blood flow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsilesional</td>
<td>−0.70</td>
<td>−2.13</td>
<td>0.033</td>
</tr>
<tr>
<td>Contralateral</td>
<td>−0.57</td>
<td>−3.21</td>
<td>0.001</td>
</tr>
<tr>
<td>Velocity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsilesional</td>
<td>−0.028</td>
<td>−0.24</td>
<td>0.81</td>
</tr>
<tr>
<td>Contralateral</td>
<td>0.036</td>
<td>0.68</td>
<td>0.50</td>
</tr>
</tbody>
</table>

reflection of brain hemodynamics. The current study confirmed that DCS is sensitive to changes in CBF with HOB angle manipulation as previously observed. Specifically, microvascular CBF increased with a lower HOB angle when averaged across the cohort. In contrast, MFV in proximal arterioles measured by TCD did not change significantly. Substantial individual variability was also observed.

One previous study measured MCA velocity with TCD during similar HOB manipulation and found the velocity to increase with lower HOB among patients with large artery occlusion. An other study similarly found that MFV increased at lower HOB angles in the setting of incomplete vessel recanalization, but with recanalization, CBF did not vary across HOB angles. Note that although there has been some concern that recanalization is associated with hemorrhagic transformation, pooled data suggest that spontaneous recanalization does not carry such risk. Our study failed to detect changes in flow velocity measured by TCD across HOB positions, even in patients with ipsilateral large artery occlusion at the time of admission, but recanalization was not addressed in the current study. The observed differences in flow relative to recanalization may be explained by differences in study timing. In this study, patients were examined 2 to 3 days after stroke onset, whereas previous studies measured blood velocity at earlier time points. The evolution of autoregulation impairment after stroke is poorly understood, but impairment is likely maximal in the acute setting. Additionally, TCD-based assessments of CBF must be interpreted with caution as this assumes a constant arterial diameter.

The results of the current study suggest that TCD MFV may not be an optimal surrogate for CBF. Several possible mechanisms may explain the discordance between MFV and CBF. First, MCA diameter may not remain constant with HOB manipulation. Second, collateral flow sources may contribute to cortical CBF not reflected in MCA MFV because DCS measures CBF in the microvasculature of the cortical surface, which TCD cannot detect. This finding is consistent with previous studies, wherein DCS correlated with TCD in healthy volunteers but diverged in patients with severe carotid artery stenosis or occlusion. The greater sensitivity of DCS underscores its potential value as a noninvasive bedside monitor of cortical CBF.

Compared with healthy volunteers, unilateral AIS patients experience larger CBF changes with HOB manipulation, which is consistent with previous reports and is thought to represent autoregulatory impairment. Although HOB effects were most pronounced in patients with ipsilesional large artery occlusion, lowering the HOB can increase CBF irrespective of vessel occlusion. However, patients with severe arterial disease may be the most likely to benefit from flat HOB positioning.

The use of a flat HOB after stroke is not consistent at all stroke centers and should be considered in the context of the patient’s ability to tolerate positioning safely with regard to aspiration risk, congestive heart failure, and intracranial pressure changes. Significant CBF changes were observed 2 and 3 days after symptom onset, indicating that a flat HOB has the potential to increase CBF long after the onset of symptoms. It is not yet known whether such flow changes influence long-term clinical outcomes given the potential rapid reduction in penumbral tissue after the first 24 hours and maintaining a supine position for several days may be impractical. Nonetheless, clinical responses to increased CBF with induced hypertension were reported up to 9 days after stroke, suggesting that penumbra did persist for some patients. Although the evolution of penumbra over the first few days is not well understood, if the supine position is tolerated, our findings support the use of a flat HOB acutely after a stroke, consistent with American Stroke Association guidelines. Future characterization of the evolution of CBF responses to HOB may help determine the optimal timing for liberalizing HOB restrictions, although this may ultimately be patient-specific.

Considerable individual variability in both DCS and TCD measurements with HOB manipulation was observed in patients with AIS. This extent of variability was not observed in healthy volunteers, suggesting that it reflects underlying pathophysiology. Although we investigated the potential sources for such variability, we found no relationship between CBF changes and either stroke volume or stroke–probe distance. The proportion of patients with a paradoxical response to HOB manipulation was also consistent in 2 independent cohorts. A paradoxical response has been reported in other
The authors attempted to identify clinical covariates that related to the paradoxical response. Although neither the mechanism of a paradoxical response nor its effects on stroke outcome are currently known, this subgroup may present a challenge to clinicians attempting to optimize perfusion acutely after a stroke. In the absence of reliable clinical identifiers, paradoxical responders might only be identifiable by real-time cortical CBF monitoring, because this subgroup could not be identified by TCD.

Conclusions

DCS provides real-time continuous monitoring of cortical CBF at bedside. Raising HOB causes a measurable decrease in CBF in most AIS patients, but the response varies widely across patients. Clinical features do not predict CBF response, emphasizing the importance of direct CBF measurements to individualize treatments. Continuous bedside monitoring of CBF using DCS can also be applied to other therapeutic interventions, such as intravenous fluid boluses or pharmacological blood pressure augmentation, with the goal of individualized therapy to optimize perfusion and improve outcome after ischemic stroke.

Acknowledgments

We thank Steven Schenkel, Brian Edlow, and Dalton Hance for help with data acquisition, and Erin Buckley for helpful discussions.

Sources of Funding

Supported by National Institutes of Health R01-NS060653 (to A.G.Y.), K24-NS058386 (to J.A.D.), R24-HD050836 (to J.A.D.), and P41-EIB015893 (to A.G.Y. and J.A.D.). São Paulo Research Foundation (FAPESP) through 2012/02500-8 (to R.C.M.) and Fundación Cellex Barcelona, Spain (to T.D.).

Disclosures

US Patent #8082015, “Optical Measurement of Tissue Blood Flow Hemodynamics and Oxygenation,” granted for the present class of diffuse correlation spectroscopy applications (Drs Yodh, Greenberg, Detre, and Durduran). Part of the technology has been transferred to a spin-off company (Hemophotonics, S.L., Barcelona, Spain), but these authors do not have any financial relationship to the company, do not have shares, and do not receive royalties. The other authors have no conflicts to report.

Table 3. Features of Paradoxical Responders

<table>
<thead>
<tr>
<th>Paradoxical Response</th>
<th>Expected Response</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y (N=10; 29%)</td>
<td>64 (13.0)</td>
<td>0.79</td>
</tr>
<tr>
<td>White race, % (N=24; 71%)</td>
<td>56 (54%)</td>
<td>0.82</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>50%</td>
<td>1.0</td>
</tr>
<tr>
<td>Admission NIHSS (N=24)</td>
<td>14 (3.7)</td>
<td>0.58</td>
</tr>
<tr>
<td>Discharge NIHSS (N=24)</td>
<td>11 (6.1)</td>
<td>0.68</td>
</tr>
<tr>
<td>Modified Rankin Scale (N=24)</td>
<td>3 (1.1)</td>
<td>0.65</td>
</tr>
<tr>
<td>Infarct volume, cm³</td>
<td>54 (57.3)</td>
<td>0.29</td>
</tr>
<tr>
<td>ASPECT score (N=24)</td>
<td>6 (2.9)</td>
<td>0.12</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>59 (21)</td>
<td>0.49</td>
</tr>
<tr>
<td>Distance (probe to infarct edge), cm</td>
<td>3.4 (1.2)</td>
<td>0.86</td>
</tr>
<tr>
<td>Proportion with MCA occlusion, %</td>
<td>20%</td>
<td>0.23</td>
</tr>
</tbody>
</table>

Comorbidities, %

| CHF (N=24) | 20% | 0.75 |
| AF (N=24)  | 20% | 0.32 |

Medications, %

| β-Blocker (N=24) | 20% | 0.32 |
| Nodal calcium channel blocker (N=24) | 0% | 0.51 |

All values are reported as mean (SD) or percentage for dichotomous variables. AF indicates atrial fibrillation; ASPECT, Alberta Stroke Program Early CT; CHF, congestive heart failure; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischemic attack.

References


Optical Bedside Monitoring of Cerebral Blood Flow in Acute Ischemic Stroke Patients During Head-of-Bed Manipulation

Christopher G. Favilla, Rickson C. Mesquita, Michael Mullen, Turgut Durduran, Xiangping Lu, Meeri N. Kim, David L. Minkoff, Scott E. Kasner, Joel H. Greenberg, Arjun G. Yodh and John A. Detre

Stroke. 2014;45:1269-1274; originally published online March 20, 2014;
doi: 10.1161/STROKEAHA.113.004116
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/45/5/1269

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2014/03/20/STROKEAHA.113.004116.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/
ONLINE SUPPLEMENT

Supplementary Figure I: Individual Responses to HOB Manipulation
Supplementary Figure I. Individual Responses to HOB Manipulation

A. Expected Response

Paradoxical Response

B. Expected Response

Paradoxical Response

Supplementary Figure Legend: Individual changes in CBF amongst (a) current cohort n=17, and (b) combined cohort n=34